Abstract Conventional CT plays an important role in the diagnosis, staging, radiotherapy target delineation, and prognosis of NSCLC, but it still has many limitations. PET/CT has been widely used in the diagnosis and treamtent of lung cancer. In particular, PET/CT metabolic parameters have great guiding significance in the prognosis of NSCLC patients undergoing radiotherapy, and may be superior to many clinical indices. This review summarizes the advances in the application of PET/CT in the prognostic evaluation of NSCLC patients undergoing radiotherapy.
Liang Meng,Zheng Rong. The application of PET/CT to predict prognosis of radiotherapy of NSCLC[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 288-291.
Liang Meng,Zheng Rong. The application of PET/CT to predict prognosis of radiotherapy of NSCLC[J]. Chinese Journal of Radiation Oncology, 2016, 25(3): 288-291.
[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.DOI:10.3322/caac.21254. [2] Manegold C,Thatcher N.Survival improvement in thoracic cancer:progress from the last decade and beyond[J].Lung Cancer,2007,57(S2):S3-S5.DOI:10.1016/S0169-5002(07)70420-8. [3] Delaney G,Barton M,Jacob S,et al. A model for decision making for the use of radiotherapy in lung cancer[J].Lancet Oncol,2003,4(2):120-128.DOI:10.1016/S1470-2045(03)00984-7. [4] 彭红,马美丽,韩宝惠.1,742例Ⅳ期非小细胞肺癌的预后分析[J].中国肺癌杂志,2011,14(4):362-366.DOI:10.3779/j.issn.1009-3419.2011.04.11. Peng H,Ma ML,Han BH.Survival analysis of 1,742 patients with stage Ⅳ non-small cell lung cancer[J].Chin J Lung Cancer,2011,14(4):362-366.DOI:10.3779/j.issn.1009-3419.2011.04.11. [5] Imamura Y,Azuma K,Kurata S,et al. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy[J].Lung Cancer,2011,71(1):49-54.DOI:10.1016/j.lungcan.2010.04.004. [6] Tann M,Sandrasegaran K,Winer-Muram HT,et al. Can FDG-PET be used to predict growth of stage Ⅰ lung cancer?[J].Clin Radiol,2008,63(8):856-863.DOI:10.1016/j.crad.2008.01.012. [7] Nair VJ,MacRae R,Sirisegaram A,et al. Pretreatment[18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy:rethinking the role of positron emission tomography in personalizing treatment based on risk status[J].Int J Radiat Oncol Biol Phys,2014,88(2):312-318.DOI:10.1016/j.ijrobp.2013.10.029. [8] Horne ZD,Clump DA,Vargo JA,et al. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy[J].Radiat Oncol,2014,9:41.DOI:10.1186/1748-717X-9-41. [9] Ulger S,Demirci NY,Eroglu FN,et al. High FDG uptake predicts poorer survival in locally advanced non-small cell lung cancer patients undergoing curative radiotherapy,independently of tumor size[J].J Cancer Res Clin Oncol,2014,140(3):495-502.DOI:10.1007/s00432-014-1591-9. [10] Zhang HQ,Yu JM,Meng X,et al. Prognostic value of serial[18F]fluorodeoxyglucose PET-CT uptake in stage Ⅲ patients with non-small cell lung cancer treated by concurrent chemoradiotherapy[J].Eur J Radiol,2011,77(1):92-96.DOI:10.1016/j.ejrad.2009.07.023. [11] Bollineni VR,Widder J,Pruim J,et al. Residual 18F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage Ⅰ non-small-cell lung cancer predicts local control[J].Int J Radiat Oncol Biol Phys,2012,83(4):e551-e555.DOI:10.1016/j.ijrobp.2012.01.012. [12] Huang W,Fan M,Liu B,et al. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy[J].J Nucl Med,2014,55(10):1584-1590.DOI:10.2967/jnumed.114.142919. [13] Im HJ,Pak K,Cheon GJ,et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer:a meta-analysis[J].Eur J Nucl Med Mol Imaging,2014(2):241-251.DOI:10.1007/s00259-014-2903-7. [14] 张华琦.FDG PET-CT预测Ⅲa/Ⅲb期非小细胞肺癌预后的临床研究[D].济南:山东省医学科学院,2010.Zhang HQ.Prognostic value of serial[18F]fluorodeoxyglucose PET-CT uptake in stage Ⅲ patients with non-small cell lung cancer treated by concurrent chemoradiotherapy[D].Ji’nan:Shandong Academy of Medical Sciences,2010. [15] 赵芬,张秀丽,孙晓蓉,等.原发灶18F-FDG PET/CT肿瘤代谢体积与晚期非小细胞肺癌患者预后的相关性研究[J].中国医学影像学杂志,2011,19(4):252-256.DOI:10.3969/j.issn.1005-5185.2011.04.004. Zhao F,Zhang XL,Sun XR,et al. Association between metabolic tumor volume from 18F-FDG PET/CT and prognosis in patients with advanced NSCLC[J].Chin J Med Imaging,2011,19(4):252-256.DOI:10.3969/j.issn.1005-5185.2011.04.004.
2016, Vol. 25 
